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Abstract
Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition has
advanced at a rapid pace over the past decade. Efflux transport proteins located in the basolateral
and apical (canalicular) membranes of hepatocytes play an important role in the hepatic
elimination of many endogenous and exogenous compounds, including drugs and metabolites.
This review focuses on the role of these efflux transporters in hepatic drug excretion. The impact
of these proteins as underlying factors for disease is highlighted, and the importance of hepatic
efflux proteins in the efficacy and toxicity of drugs is discussed. In addition, a brief overview of
methodology to evaluate the function of hepatic efflux transport proteins is provided. Current
challenges in predicting the impact of altered efflux protein function on systemic, intestinal and
hepatocyte exposure to drugs and metabolites are highlighted.
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Introduction
The liver plays an important role in the synthesis and secretion of bile acids, in the
metabolism and transport of cholesterol, and in the metabolism and efflux of endogenous
and exogenous substances by cytochrome P450 enzymes and phase II conjugation systems.
Until the latter part of the twentieth century, it was generally assumed that passive diffusion,
governed by the physicochemical properties of molecules, determines the uptake and efflux
of drugs/metabolites across the basolateral and apical membranes of hepatocytes. However,
it is now well established that transport proteins play a key role in the uptake clearance of
many drugs from hepatic sinusoidal blood, and in the excretion of parent compounds and/or
metabolites from the hepatocyte into bile, or the systemic circulation. The aim of this review
is to summarize the current knowledge of hepatic basolateral and canalicular efflux proteins.
For transporters involved in hepatic uptake processes, we refer the reader to the recently
published review by Hagenbuch et al. (1) Comprehensive reviews are referenced for details
on specific efflux transport proteins.
1. Major Hepatic Efflux Transporters
The hepatocyte is highly polarized with respect to transport systems expressed on the
basolateral/sinusoidal or apical/canalicular membrane domain. Both membrane leaflets are
separated by tight junctions that seal off the lumen of the bile canaliculi from the systemic
circulation. The large pores (fenestrae) of the sinusoidal endothelial cells allow contact of
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the basolateral membrane of hepatocytes and sinusoidal plasma. Basolateral uptake is the
first step in hepatic clearance of compounds from the systemic circulation; this explains the
high abundance of uptake transporters in the basolateral including the sodium-dependent
taurocholate cotransporting polypeptide (NTCP), the organic anion transporting
polypeptides (OATPs), organic anion transporters (OATs), and organic cation transporters
(OCTs). In contrast, efflux transporters located in both the canalicular and basolateral
membrane leaflets mediate excretion into bile or into the systemic circulation, respectively.
(Figure 1)
Apical/Canalicular Transporters
Substances are excreted into bile primarily by ATP-dependent proteins of the ABC
transporter superfamily [e.g., multidrug-resistance proteins (MDR), and the multidrug-
resistance-associated proteins (MRPs)]. More recently, the multidrug and toxin extrusion
exchanger 1 (MATE 1) has been identified as an apical efflux transporter for cations in
hepatocytes.
BSEP—Bile salt export pump (BSEP) (ABCB11), a member of the ABC transporter
superfamily, is located exclusively in the canalicular membrane of hepatocytes. BSEP has a
narrow substrate spectrum and transports primarily monoanionic, conjugated bile acids. It
exhibits high affinity for bile acids (taurochenodeoxycholate > taurocholate >
taurodeoxycholate > tauroursodeoxycholate > glycocholate). Interestingly, only a few drugs
have been described as BSEP substrates; pravastatin has been shown to be transported by
both human and rat BSEP/Bsep, and vinblastine has been identified as a substrate of mouse
Bsep. (2) In humans, BSEP appears to be the sole transporter for monoanionic bile acids
across the apical membrane; a decrease in BSEP function may lead to reduced bile acid
secretion, enhanced intracellular accumulation of bile acids, cholestasis, and, in the worst
case, progressive liver injury. Indeed, BSEP deficiency results in several genetic forms of
cholestasis, such as progressive familial intrahepatic cholestasis type 2 (PFIC2) and benign
recurrent intrahepatic cholestasis type 2 (BRIC2). In addition, this protein has been
implicated in drug-induced cholestasis mediated by interactions between drugs and
endogenous compounds, and intrahepatic cholestasis of pregnancy. (3)
P-glycoprotein (P-gp)—P-glycoprotein (MDR1, ABCB1) was one of the first
transporters recognized as having an important role in drug distribution and elimination. P-
gp was first identified by Juliano and Ling in 1976 in Chinese hamster ovary cells that were
selected for colchicine resistance, and that displayed resistance to a wide range of
amphiphilic drugs. P-gp functions as an efflux pump for a wide range of substances
including amphiphilic bulky cationic drugs, as well as for steroid hormones, hydrophobic
peptides, and glycolipids. (see (4) for review) P-gp is expressed in many biological
interfaces, including the intestine, liver, the blood-brain and placental barriers, and the
kidney, suggesting that this protein plays an important role in the distribution of xenobiotics
and endogenous substances. In the liver, P-gp is expressed in the canalicular membrane of
hepatocytes. However, hepatic P-gp expression levels are approximately sevenfold lower
than in the intestine. (5) Furthermore, high interindividual differences in expression levels
(50-fold) have been reported. (6) The relative contribution of hepatic P-gp to the overall
disposition of substrate drugs in humans has been questioned.
MRP2—MRP2 (ABCC2) is an organic anion transporter expressed in the apical membrane
of polarized cells such as hepatocytes, renal cells, enterocytes and placental cells. It plays a
key role in the biliary elimination of glucuronide and sulfate conjugates, and divalent bile
acids. (reviewed in (7)) MRP2 is involved in the biliary excretion of glutathione, which is a
major osmolyte and a factor that determines bile-salt-independent bile flow. (8) MRP2
Kock and Brouwer Page 2













maintains a steep concentration gradient of GSH between blood and bile (GSH in bile = 10–
15 mmol/l; GSH in blood = 100 μmol/l), thereby drawing water into the bile. This was
supported by the observation that animals lacking functional MRP2 (e.g., TR- or Esai
hyperbilirubinemic rats (EHBR) rats) exhibited a bile flow rate approximately twofold lower
than that in control animals. (9) As discussed below, MRP2 deficiency is associated with
Dubin-Johnson-syndrome (DJS) and results in hyperbilirubinemia, due to impaired
extrusion of bilirubin glucuronide into bile via MRP2. As a compensatory mechanism,
upregulation of MRP3 increases transport of bilirubin glucuronide across the sinusoidal
membrane. (10)
BCRP—The breast cancer resistance protein BCRP (ABCG2) was first described in
multidrug-resistant cell lines, in which it was shown to confer resistance to cytotoxic
compounds such as mitoxantrone, topotecan, irinotecan, and doxorubicin. Given its
expression in blood-tissue barriers such as the blood-brain barrier, the intestine, and the
placental barrier, BCRP is believed to have a major role in protecting physiologic barriers.
Because of its broad substrate specificity, including specificity to anticancer agents and
environmental carcinogens, BCRP has been associated with multidrug resistance and tumor
development/progression. In the liver, BCRP is expressed in the canalicular membrane of
hepatocytes. Numerous studies have demonstrated the important role of BCRP in the biliary
elimination of substrates. In Bcrp knockout mice, the biliary excretion rates of methotrexate,
the HMG-CoA-reductase inhibitors pitavastatin and rosuvastatin, and fluoroquinolones were
significantly lower than in wild-type mice, as published in a recent review. (11)
MATE—The discovery of MATE proteins explained how organic cations are excreted
across the apical membrane in the liver and kidney. MATE proteins were identified
originally as bacterial transporters. However, in 2005, two human MATE transporter
proteins, MATE1 and MATE2, were identified on the basis of gene sequence similarity.
(12) In contrast to other canalicular drug efflux transporters, MATE proteins belong to the
solute carrier family 47 (SLC47) and function as secondary transport systems that utilize the
electrochemical gradient of cations across the membrane for substrate transport, which may
occur in both directions. Human MATE proteins mediate the excretion of compounds into
bile and urine on the basis of H+/organic cation antiport. MATE1 demonstrates predominant
expression in the canalicular membrane of hepatocytes, but it can also be found in the
kidney, skeletal muscle, adrenal gland, and testis. MATE2, on the other hand, is almost
exclusively expressed in the luminal membrane of proximal renal tubular epithelial cells.
Substrates of MATE proteins include the organic cations creatinine, guanidine, and
thiamine, as well as numerous drugs such as metformin, cimetidine, oxaliplatin, acyclovir,
and fexofenadine. In the liver, organic cation transporter 1 (OCT1) may function in concert
with MATE1 to mediate the hepatic uptake and biliary excretion, respectively, of cationic
drugs and their metabolites. (13)
Basolateral/sinusoidal transporters
Basolateral efflux transporters mediate the removal of endogenous and xenobiotic
compounds from the hepatocyte into sinusoidal blood. Transporters suggested to be
involved in basolateral efflux processes include MRP3, MRP4, MRP5, and OSTα/β.
MRP3—MRP3 (ABCC3), an organic anion transporter expressed in the liver, kidney,
intestine, adrenals, and pancreas, is localized to the basolateral membrane in polarized
epithelial cells. (14) In the human liver, prominent MRP3 staining of cholangiocytes and
weak staining of hepatocytes around the portal tract have been shown. However, hepatic
MRP3 protein expression is highly variable (up to 85-fold) and highly inducible. (15) For
example, in humans, MRP3 expression is upregulated in the absence of functional MRP2,
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such as in patients with DJS (16), and under cholestatic conditions when the biliary
excretion of organic anions via the canalicular membrane of the hepatocyte is impaired. (17)
Originally, it was hypothesized that human MRP3 plays a role in hepatocellular bile acid
homeostasis based on a report that rat Mrp3 transported conjugated bile acids with rather
high affinity. (18) However, it was later discovered that human MRP3 transports bile acids
only with low affinity. (19) The clinical relevance of human MRP3 as an important
compensatory bile acid efflux pump remains to be established. In Mrp3 knockout mice,
there was no evidence of the expected differences in serum bile acid concentrations and
hepatic injury after bile duct ligation. (20) However, because of a high affinity for
glucuronide conjugates (e.g., morphine-3-glucuronide, bilirubin-glucuronide, etoposide-
glucuronide, and acetaminophen-glucuronide), it has been suggested that MRP3 has a
defense related function and contributes to the excretion of toxic anions. In this context,
MRP3 may act as a switch to change the excretion route from bile to urine under
pathological conditions.
MRP4—MRP4 (ABCC4) is expressed widely in normal tissues and has been implicated in
the transport of antiviral agents (e.g., azidothymidin, adefovir, and ganciclovir), anticancer
agents (e.g. methotrexate, 6-mercaptopurin, and camptothecins) and cardiovascular agents
(loop diuretics, thiazides, and angiotensin II receptor antagonists), as well as of endogenous
substances such as steroid hormones, prostaglandins, bile acids, and the cyclic nucleotides
cAMP and cGMP. Sulfated conjugates of bile acids and steroids have high affinity for
MRP4. (21) Although no specific disease has been linked directly to altered MRP4 activity,
the sinusoidal expression of this protein in hepatocytes, its ability to transport bile acids, and
its increased expression in human and rat livers under cholestatic conditions (22, 23) support
the hypothesis that MRP4 is an important component of the protective system of
hepatocytes. In support of this hypothesis – and in contrast to the findings in Mrp3 knockout
mice – cholestasis induced by bile duct ligation in Mrp4 knockout mice resulted in increased
liver toxicity as compared with bile-duct ligated wild-type mice. (24)
MRP5—MRP5 (ABCC5), another member of the ABCC subfamily, is expressed primarily
in the colon, liver, kidney and brain. In mice and humans, Mrp5/MRP5 is expressed at
relatively low levels in healthy liver; however, MRP5 mRNA and protein are upregulated in
patients with primary biliary cirrhosis. (25). Currently, it is not known whether MRP5
participates in hepatic drug transport.
OSTα/β—OSTα/β was identified in 2001 as a novel organic solute and steroid transporter
in the little skate Leucoraja erinacea (26); in 2003, mouse and human orthologs were
identified and cloned. (27) In vitro transfection experiments have shown that OSTα and
OSTβ function as heteromeric proteins, and that c-expression of the two is required for
delivery to the plasma membrane and functional activity. In human tissues, mRNA of OSTα
and OSTβ is expressed widely; the highest expression levels are in tissues involved in
steroid and bile acid homeostasis such as the small intestine, liver, colon, kidney, testes,
ovaries, and adrenal gland. OSTα/β substrates include steroid hormones and endogenous
compounds such as estrone sulfate and dehydroepiandrosterone sulfate, bile acids, and
PGE2, as well as the cardiac glycoside digoxin. (28) Ballatori et al. showed that OSTα/β-
mediated transport is bidirectional, ATP-independent, and unaffected by changes in
transmembrane electrolyte concentrations and changes in pH gradients, suggesting that the
transport takes place via facilitated diffusion. (29) Depending on the extent of the
electrochemical gradient, either efflux or uptake of substrates can take place. To date, no
human disease has been associated with impaired OSTα/β function. However, the
expression of this protein in organs involved in bile acid homeostasis, including the intestine
and liver, suggests that this transporter might be involved in diseases associated with bile
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acid malabsorption or cholestasis. The participation of OSTα/β in bile acid transport in the
intestine has been demonstrated in knockout animal models, but its role in bile acid
disposition in the liver is less clear.
2. Efflux Transport Proteins as Underlying Factors for Disease
The importance of hepatic efflux proteins in liver function is best exemplified by two
diseases in humans, both of with associated with reduced/missing function of drug efflux
carriers: PFIC and DJS. The elucidation of the biochemical mechanisms underlying these
diseases, highlighted in the following section, played a key role in the early discovery and
characterization of hepatic transport proteins and improved our understanding of the
function of these proteins in the hepatic disposition of endogenous and exogenous
substances.
Progressive Familial Intrahepatic Cholestasis (PFIC)
Bile formation is a major function of the liver. After synthesis from cholesterol, bile acids
are secreted via the biliary tree into the intestine, where they are involved in ingestion of
fatty acids and fat-soluble vitamins. Along the small intestine, transport proteins facilitate
bile acid reabsorption across the intestinal epithelial cells into the portal circulation and back
to the liver. From the portal blood, bile acids are taken up into hepatocytes and the process
of enterohepatic circulation is repeated. It is well established that hepatic bile acid secretion
and enterohepatic circulation require the coordinated action of distinct uptake and efflux
transporters on the apical and basolateral membranes of enterocytes and hepatocytes.
Initially, the electrochemical gradient across the canalicular membrane of the hepatocyte
was thought to be the driving force for bile acid secretion into bile; however, this gradient
was found to be insufficient to act as a driving force for the high concentrations of bile acids
achieved in bile. The membrane potential across the canalicular lumen of approximately −35
mV would account for a gradient of only 1:3, whereas in vivo cell-to-bile acid concentration
gradients of 1:10 to 1:100 are reached. In the early 1990s, studies in isolated membrane
vesicles from rat and human liver demonstrated that canalicular bile acid transport is an
ATP-dependent process. (30, 31) In 1995, a gene known as sister of P-gp (Spgp) was cloned
by Childs et al. from a pig cDNA library using low stringency screening with a probe
sequence from the multidrug-resistance gene MDR1. (32) MDR1 and Spgp shared 61%
amino acid identity. Tissue expression of the Spgp mRNA was detected almost exclusively
in canalicular microvilli and in subcanalicular smooth membrane vesicles of rat liver,
suggesting that it may be a candidate for ATP-dependent bile acid transport. Indeed, Gerloff
et al. demonstrated bile acid transport in Xenopus leavis oocytes injected with rat Spgp, and
in membrane vesicles from Sf9 cells transfected with rat Spgp cDNA. (33) With these
systems, it was shown that Spgp functions as an ATP-dependent bile acid transporter, and
the protein was renamed the “bile salt export pump” (BSEP/Bsep). Human BSEP, the
functional expression of which observed and characterized in 2002, also acts as a bile acid
transporter.
In the late 1990s, a link was identified between PFIC type 2 and BSEP mutations, and this
disease was mapped to chromosome 2q24 where BSEP is encoded. (34) PFIC is a very
heterogeneous group of autosomal recessive liver disorders leading to intrahepatic
cholestasis. On the basis of clinical, biochemical, and histological features, PFIC can be
divided into three types that are associated with mutations in ATP8A1 (PFIC type 1),
ABCB11 (PFIC type 2), and ABCB4 (PFIC type 3). (35) The findings in patients with
mutations in the ABCB11/BSEP gene are characterized by normal γ-glutamyltransferase
activity, decreased biliary bile acid concentrations, and the absence of bile duct proliferation.
The importance of BSEP function is highlighted by the fact that patients with PFIC type 2
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secrete <1% of bile acids into bile as compared with normal individuals. (36) These findings
also suggest that there is no backup system for BSEP in the canalicular membrane. Without
treatment, PFIC results in cirrhosis, which rapidly progresses to hepatic failure and often
requires liver transplantation before the patient reaches adolescence. (37) Several premature
termination, missense, and frameshift mutations have been identified in patients with PFIC
type 2; these mutations impair trafficking to the canalicular membrane and/or transport
activity. (38) (Figure 2) A recent study in BSEP patients demonstrated that the D482G
mutation is associated with slower disease progression, consistent with data that the D482G
BSEP protein retains some functional activity. (39) Furthermore, these patients develop
cirrhosis later in life and thus require liver transplantation later than other PFIC type 2
patients. (40).
Dubin-Johnson Syndrome
First described in 1954, DJS is a rare autosomal recessive disorder, characterized by
impaired secretion of organic anions such as bilirubin glucuronide, a black liver due to
bilirubin accumulation, and conjugated hyperbilirubinemia in plasma. (41) It had long been
assumed that this syndrome was the result of a canalicular secretion defect; however, the
underlying mechanism for this disorder was not identified until 1997, when a mutation in the
ABCC2 gene was determined to be responsible for impaired expression and function of the
multidrug resistance associated protein 2 (MRP2, Figure 3). (42) One year earlier,
Kartenbeck et al. had used an antibody directed against MRP1 (a protein related to MRP2)
to demonstrate the absence of canalicular immunostaining in the liver section of a DJS
patient. This antibody demonstrated lateral and canalicular staining in liver samples from
healthy individuals, but only lateral staining in those from patients with DJS. (43)
Subsequently, it was determined that this antibody crossreacts with MRP2, detecting the
apically localized MRP2 and as possibly the lateral/basolateral MRP1as well.
The important discovery that loss-of-function of MRP2 is the mechanism underlying DJS
was facilitated by the description and characterization of rat strains with inherited,
conjugated hyperbilirubinemia, which resemble the findings in human DJS. The mutant TR-/
GY (Groningen Yellow) Wistar rat strain was first identified by Jansen et al. (9) A similar
mutant strain, EHBR, was identified in Sprague-Dawley rats in 1986 in Japan by Mikami et
al. (44) Both mutant rat strains are deficient in the canalicular transport of a variety of
anionic conjugates such as bilirubin glucuronide, and glutathione and sulfate conjugates of
endogenous and exogenous compounds. Interestingly, recent studies have revealed that TR-
rats also exhibit low expression levels of Bcrp protein. (45) Even before members of the
ATP superfamily were cloned and functionally characterized, these mutant rat strains
provided information on the functional capabilities of a postulated transport protein referred
to as canalicular multispecific organic anion transporter (cMOAT), non-bile acid organic
anion transporter, glutathione S-conjugate export pump, or leukotriene export pump. The
biliary excretion of the radiolabeled glutathione S-conjugate of leukotriene C4 (LTC4), a
compound later identified as a high-affinity MRP2 substrate, was significantly lower in TR-
rats. (46) Transport measurements carried out on inside-out canalicular membrane vesicles
prepared from these mutant rat strains contributed further to our knowledge of substrate
specificity. For example, ATP-dependent LTC4 transport was significantly impaired in
canalicular membrane vesicles prepared from transport-deficient TR- rats. (47)
The identification of the ABCC2 gene was facilitated by the prior identification of MRP1,
which conferred multidrug-resistance in a lung cancer cell line (48); PCR, based on
conserved domains of ABCC1, demonstrated a lack of amplification of a 347-bp fragment in
TR- but not in normal Wistar rat hepatocytes. Furthermore, the sequence of the amplified
fragment was MRP1-like but differed significantly from the cDNA encoding rat Mrp1,
indicating the absence of an Abcc transporter isoform in this rat strain. (49) Subsequently, in
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1996, cloning and sequencing of rat Mrp2 revealed a nucleotide deletion in the Abcc2 gene
of TR- rats. (50) Human cDNA was cloned in the same year from a cisplatin-resistant cell
line. (51) Since then, ABCC2/Abcc2 proteins have been expressed and characterized in
detail. (7) The contribution of Mrp2 in the pathogenesis of the DJS-like phenotype in rats
was confirmed by infecting EHBR rats with an adenovirus carrying ABCC2, which
compensated for the genetic defect and corrected the canalicular transport deficiency. (52)
3. Hepatic Efflux Transport Proteins as Determinants of Pharmacokinetics,
Efficacy and Side Effects of Drugs
Drug-induced enteropathy and diarrhea
Biliary excretion is one route of elimination for many endogenous compounds such as
bilirubin and hormones, as well as for some xenobiotics and their metabolites. Interestingly,
in certain cases, the biliary excretion of drugs and/or metabolites may be responsible for
injury to the small intestine (enteropathy) and diarrhea. Nonsteroidal anti-inflammatory
agents (NSAIDs), irinotecan, and mycophenolic acid are examples of drugs associated with
a high risk of drug-induced enteropathy and diarrhea. The role of hepatic efflux transporters
in the adverse events associated with these drugs is discussed in the following section.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with gastric injury and
are being recognized increasingly as a cause of enteropathy. Recent data using video capsule
imaging studies demonstrated an incidence of intestinal damage of ~60% in subjects taking
NSAIDs for a 2-week period. (53, 54) The gastric side effects of NSAIDs are well
understood, but the pathophysiological mechanisms of enteropathy, characterized by
inflammation and lesions in the small intestine, blood loss, increased permeability, and bile
acid malabsorption, are far less clear.
Most NSAIDs, including ibuprofen, diclofenac, ketoprofen, and indomethacin, undergo
UGT-mediated biotransformation to form a reactive acyl glucuronide, which can then form
adducts with proteins. This acyl glucuronide formation has been suggested to be the major
toxicokinetic determinant. Drug conjugates are excreted into bile and move into the distal
regions of the intestine, where they are deconjugated by bacterial glucuronidases, leading to
high local concentrations of the parent compound. (55) Several studies have suggested that
intestinal colonization with different types of bacteria plays a significant role in the
development of NSAID-associated enteropathy, and that the deconjugation capacity of
bacteria might be an important factor in causing intestinal damage. Medications that
influence the number and/or types of intestinal bacteria, such as antibiotics or proton pump
inhibitors, might exacerbate NSAID-induced intestinal damage. (56, 57)
In the 1970s, biliary excretion and enterohepatic circulation were identified as important
factors in the development of NSAID enteropathy; bile-duct ligation in rats prevented
intestinal damage. (58, 59) This was substantiated by the observation that NSAIDs with
limited enterohepatic circulation did not cause intestinal damage in animal models. (60)
Further experiments in MRP2-deficient EHBR and TR- rats demonstrated the key role of
Mrp2 in the development of this side effect; rats deficient in Mrp2 exhibited lower levels of
adduct formation and ulceration. (61) Mrp2-deficient rats excreted 50% less indomethacin
glucuronide and 98% less diclofenac glucuronide into bile as compared with wild-type rats.
(61) Transfer of diclofenac glucuronide-containing bile from diclofenac-treated wild-type
rats into the intestine of TR- rats significantly increased intestinal damage, demonstrating
that biliary excretion is involved in the pathogenesis of small-intestine injury. (62)
Irinotecan, (CPT-11, Figure 4) a topoisomerase 1 inhibitor, is used widely as an anticancer
agent, particularly in the treatment of colorectal cancer, lung cancer and malignant
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melanoma. Clinical use of irinotecan is associated with myelotoxicity and dose-limiting
severe diarrhea in 5–40% of patients. (63) After administration by intravenous injection,
irinotecan is hydrolyzed by hepatic carboxylesterases to the active SN-38 form, followed by
inactivation by CYP-mediated oxidation or glucuronidation. Extensive amounts of
irinotecan, SN-38 and SN-38 glucuronide (SN-38G) are excreted into the bile and intestine
via several ATP-binding cassette transporters, including P-gp, MRP2, and BCRP (Figure 4).
(64, 65) In the human intestine, active SN-38 can be formed from irinotecan via intestinal
carboxylesterases or by deconjugation of SN-38G by bacterial β-glucuronidases, and then
reabsorbed resulting in a secondary peak in the systemic concentration-time profile. (66) It
has been hypothesized that repeated exposure of SN-38 to enterocytes by enterohepatic
circulation is the cause of diarrhea.
Numerous investigators have attempted to identify the environmental and genetic factors
that affect the pharmacokinetic profile of SN-38 in an effort to predict side effects and
individualize dosage regimens for patients. A major breakthrough in therapy was the
evidence linking the low glucuronidation capacity of SN-38 to an increased risk of
irinotecan-induced neutropenia. SN-38 is glucuronidated predominantly by UGT1A1.
UGT1A1*28, which is characterized by seven TA repeats in the TATA element of UGT1A1
promoter (the wild-type genotype has six repeats), demonstrated lower expression levels and
function and has been associated with irinotecan hemotoxicity. On the basis of these
findings, the U.S. Food and Drug Administration (FDA) approved a label change for
Camptosar® (irinotecan hydrochloride) to include recommended dosage adjustments for
patients with the UGT1A1*28 allele. (67)
Although there is strong evidence linking glucuronidation capacity with neutropenia, the
association with diarrhea is less clear; approximately one half of irinotecan-treated patients
with severe diarrhea have the UGT1A1*28 genotype. (68) This suggests that there are other
mechanisms, apart from UGT activity, that affect the pharmacokinetic and side effect
profiles of irinotecan.
The hepatic uptake transporter OATP1B1 has been shown to transport SN38, the active
metabolite of irinotecan; several clinical studies have highlighted the importance of this
protein in the disposition of SN38. (69, 70) Furthermore, the drug efflux transporters P-gp,
MRP2, and BCRP have been implicated in the disposition and toxicity of irinotecan, SN-38,
and SN38G because of their involvement in biliary excretion. (64, 65) Two studies in
patients with lung cancer demonstrated an association between the P-gp 3435TT genotype
(which results in a lower plasma AUC for SN38G) and a higher incidence of diarrhea. (71,
72)
It has been suggested that functional variants in MRP2 (such as ABCC2 3972C>T) have
profound effects on the pharmacokinetics, efficacy, and toxicity of irinotecan. (72, 73) De
Jong et al. demonstrated that patients carrying the haplotype ABCC2*2 (low activity)
exhibited a lower irinotecan clearance and less severe diarrhea if they did not carry the
UGT1A1*28 allele, suggesting that MRP2 and glucuronidation play an important role in
intestinal side effects. (73) One hypothesis that could explain this observation is that the
reduction in MRP2-mediated biliary excretion due to the ABCC2*2 haplotype leads to
decreased intestinal formation of SN-38 locally. However, the presence of an UGT1A1*28
allele, and consequently the reduced detoxification and increased exposure to SN-38 in the
enterocytes, could counteract this protection. (73)
Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is a commonly
used immunosuppressant for the prevention of transplant rejection. Like irinotecan, MMF
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therapy is associated with severe side effects including gastrointestinal complications and
bone marrow suppression leading to dose reduction or drug discontinuation.
After oral administration, MMF is hydrolyzed rapidly to the active MPA by esterases
located in the gut wall, the liver, and the systemic circulation. In the liver, MPA is
metabolized predominantly to the inactive MPA-phenyl-glucuronide (MPAG) and, to a
lesser extent, to the active MPA-acyl-glucuronide (AcMPAG). (74, 75) Although the kidney
is the major organ involved in MPA elimination, MPA-glucuronides undergo biliary
excretion, intestinal deconjugation, and reabsorption as MPA resulting in a secondary peak
in the MPA concentration-time profile, which contributes between 10 and 60% to the AUC
of MPA. (76, 77) Although there does not appear to be an association between plasma AUC
and diarrhea, (78) increased intestinal exposure to MPA due to biliary excretion of MPA
glucuronides seems to be associated with the onset of diarrhea. Experiments in Mrp2-
deficient EHBR and TR- rats, and co-treatment with the MRP2 inhibitor cyclosporin A,
demonstrated that MRP2 is the major transporter involved in the biliary excretion of MPAG
and AcMPAG. (79, 80) These observations prompted a series of studies investigating the
role of MRP2 polymorphisms in the development of diarrhea. The studies focused on the
ABCC2 C-24T promoter variant, which has been associated with altered expression and
activity of MRP2. (81) To date, two studies – one in pediatric heart transplant patients and
adult renal transplant patients reported a significantly higher incidence of diarrhea in
patients expressing the ABCC2 C-24T promoter variant. However, three studies in patients
after renal transplant failed to show this relationship. (82–86) These controversial data
suggest that other factors are involved in the development of intestinal injury during MPA
therapy, including UGT-mediated glucuronidation and/or local bioactivation by the
intestinal microflora.
Drug-induced Liver Injury
Drug-induced liver injury (DILI) is a serious adverse event that often results in the
withdrawal of drugs from the market and is one of the leading causes for the failure of drug
candidates in development. Although several mechanisms may be involved in the
pathogenesis of DILI including reactive metabolite formation, mitochondrial toxicity, and
immunologic reactions, hepatobiliary transporters are postulated to be important
contributors to the hepatotoxicity associated with some medications. In principle, either of
two mechanisms may account for the involvement of transporters in the pathogenesis of
DILI: (i) direct transport of potentially hepatotoxic compounds or metabolites, or (ii)
interaction of drugs or metabolites with the excretion of potentially hepatotoxic bile acids.
The hepatobiliary disposition of drugs and bile acids is governed by hepatic uptake,
metabolism, and excretion. It has become increasingly clear that modifications in these
processes, either by drug-drug interactions, disease states, or genetic variation, can greatly
influence the disposition of potentially toxic endogenous and exogenous compounds.
Currently, little information is available regarding the involvement of basolateral uptake
transporters such as OATPs, OCTs, and OATs in the development of DILI. However,
several drugs associated with DILI are substrates for these uptake transporters; therefore,
enhanced expression or function of these uptake transporters might increase hepatocyte
concentrations of hepatotoxic compounds.
In contrast to the relative paucity of information relating to uptake transporters in the
development of DILI, more information is available on the impact of efflux transporters,
especially BSEP. As described above, BSEP primarily governs the biliary excretion of bile
acids under normal physiologil conditions. Inherited dysfunction of BSEP leads to
cholestatic syndromes (PFIC, BRIC) and cholestatic liver injury. Several drugs associated
with DILI are potent inhibitors of BSEP, including cyclosporin A, bosentan, troglitazone,
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sulindac, rifamycin, and glibenclamide. (87, 88) The metabolites of a drug may also
contribute to its hepatotoxic potential. For example, troglitazone sulfate exhibits 10-fold
more potent inhibition of Bsep-mediated taurocholate transport than troglitazone in
canalicular plasma membrane vesicles isolated from rat liver. (88) Extensive hepatocellular
accumulation of troglitazone sulfate due to impaired canalicular and/or basolateral efflux,
may increase the susceptibility of some patients to liver injury mediated by troglitazone.
(89) The results of a recent study that screened 200 compounds for BSEP inhibition
suggested a strong association between the pharmacologic interference of this transporter
and liver toxicity (Figure 4). (90) However, the low incidence of DILI suggests that other
factors – genetic or environmental – are involved in the pathogenesis of DILI, predisposing
some patients to develop this deleterious side effect. MRP3 and MRP4 are two basolateral
proteins that are involved in bile acid efflux from hepatocytes, especially when biliary
excretion is impaired. Studies in humans and bile duct-ligated rats have demonstrated that
these transporters are upregulated under cholestatic conditions. (14, 23) The development of
cholestatic liver injury after treatment with a BSEP inhibitor might be dependent on the
expression and function of these basolateral efflux transporters that normally counteract
increases in intracellular concentrations of potentially hepatotoxic bile acids.
In addition to inhibition of bile acid transport, the hepatic disposition of toxic drugs and/or
metabolites may be an underlying cause of liver injury. For example, patients with an MRP2
polymorphism associated with reduced function (C-24T) have a five- to sixfold higher risk
of developing hepatotoxicity after taking diclofenac, probably due to increased intracellular
accumulation of reactive metabolites and higher levels of toxic protein adducts. (91)
Trabectedin, a promising anticancer drug, exhibits dose-limiting hepatotoxicity. Mrp2 and
other hepatic efflux proteins protect against trabectedin-mediated hepatotoxicity as shown in
studies in sandwich-cultured rat hepatocytes. (92) The importance of Cyp3a-generated
metabolites in trabectedin hepatotoxicity, as well as the protection afforded by drug efflux
proteins, was confirmed by studies in transporter knockout mice; only mild hepatotoxicity
was observed in Cyp3a/Abcb1a/1b/Abcc2−/− mice in contrast to the severe toxicity seen in
Abcb1a/1b/Abcc2−/− mice. (93)
Statins
HMG-CoA reductase inhibitors, commonly referred to as “statins”, are prescribed for the
treatment of hypercholesterolemia, a major risk factor for cardiovascular disease; statins are
among the most widely used drugs worldwide. The major target of statins is inhibition of the
hepatic synthesis of mevalonate, the rate-limiting step in cholesterol biosynthesis. Although
statins are generally well tolerated, plasma-concentration dependent myopathy is a side
effect characterized by muscle pain, fatigue, and cramping, which ranges from mild myalgia
to life-threatening rhabdomyolysis. High interindividual variability in plasma concentrations
is a characteristic of statins; plasma concentrations and toxicity may be influenced by
hepatic drug transporters. Expression of OATP1B1, an influx transporter localized on the
basolateral membrane of human hepatocytes, influences the pharmacokinetic profile as well
as the myotoxicity of statins. Individuals expressing the c.521CC genotype exhibited higher
plasma AUCs after administration of simvastatin, atorvastatin, and pitavastatin compared to
those expressing the c.521TT genotype, probably due to decreased hepatic uptake of statins.
Furthermore, the c.521T>C SNP has been associated with simvastatin-induced myopathy
and a slight reduction in cholesterol-lowering efficacy (comprehensively reviewed in (94)).
Statins are also substrates of drug efflux transporters, including BCRP. Clinical implications
have been reported in patients with the c.421C>A SNP, which reduces the transport function
of BCRP. (95, 96) Subjects expressing at least one variant BCRP 421A allele were more
likely to attain LDL cholesterol target concentrations after treatment with rosuvastatin. (97)
A plausible mechanism is decreased hepatic efflux, leading to higher intracellular
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concentrations and increased efficacy in patients carrying this variant genotype (Figure 5).
However, BCRP also is expressed in the apical membrane of enterocytes where it limits the
absorption of rosuvastatin from the small intestine. (98) Carriers of the 421 allele also had
higher AUCs and higher peak concentrations of rosuvastatin and atorvastatin in plasma. (99,
100) These studies suggest that the greater efficacy of rosuvastatin in patients carrying the
variant BCRP allele might be attributable to a combination of increased plasma rosuvastatin
concentrations and increased hepatocyte exposure.
Morphine, MRP3, and antinociception
Morphine is a potent opiate analgesic that is used clinically to treat severe acute and chronic
pain. A major obstacle in therapy is the development of drug tolerance, which necessitates
dose increases and further elevates the risk of side effects. Furthermore, plasma
concentrations of morphine and its metabolites vary considerably between patients, and it is
necessary to titrate the dose according to the pain. In humans, morphine primarily undergoes
hepatic metabolism to morphine-3-glucuronide (M3G; 60%) and morphine-6-glucuronide
(M6G; 6–10%), which is mediated by UDP-glucuronosyl transferase 2B7 (UGT2B7); (101)
a large amount of the dose is excreted in urine, predominantly in the form of the glucuronide
metabolites. (102) In humans, M6G is the major active metabolite of morphine, and is more
potent than the parent compound, while M3G has no analgesic properties and even
antagonizes the effect of morphine. (103) Compared to the parent compound, the
glucuronide metabolites are more polar, which limits diffusion through membranes.
Morphine-glucuronide conjugates must be transported into the systemic circulation by efflux
proteins on the basolateral membrane of hepatocytes; MRP3 has been suggested as a
possible transport protein (Figure 5). (16, 104) Indeed, higher amounts of M3G were
recovered in liver and bile of Mrp3 knockout mice; plasma M3G concentrations were
reduced 50-fold, suggesting that Mrp3 is involved in the excretion of morphine-glucuronides
from hepatocytes into the systemic circulation (M6G is not formed in mice). (105) Human
MRP3 also transports M6G, which may influence morphine disposition and analgesic
potency. Recently, several MRP3 polymorphisms have been identified; however, these
variant alleles had very low frequencies and displayed inter-ethnic variability. (106) As
mentioned previously, MRP3 expression in human liver is low, but quite variable (up to 80-
fold). (107) These differences in MRP3 expression and/or function may influence
interindividual differences in morphine pharmacokinetics and pharmacodynamics.
4. Methods to Study the Function of Drug Efflux Transporters
As highlighted in the previous sections, efflux transporters play a major role in the hepatic
physiology/pathophysiology as well as the pharmacological behavior of drugs. Hepatic
efflux transporters can significantly influence the efficacy, side effects and toxicity of some
drugs. However, we do not yet have a comprehensive understanding of the role of hepatic
efflux transporters in clinical pharmacology, in part, because of current limitations in the
model systems and techniques available to study hepatic efflux transporters in humans.
In vivo pharmacokinetic/pharmacodynamic studies in humans are the gold standard for
identifying clinically significant contributions of transport proteins to drug disposition.
Unfortunately, the complexity of the hepatobiliary system, with broad substrate overlap of
transporters and limited access in vivo, makes it difficult to identify the functions of specific
efflux proteins in the human liver. Studies in patients with polymorphisms in transporter
genes might help to elucidate the contributions of single efflux proteins. However,
pharmacokinetic analyses based on plasma drug concentrations in clinical studies provide
information only on the overall systemic clearance; differentiation between altered hepatic
uptake and canalicular efflux is not possible without additional data (e.g., hepatocyte
concentrations and/or biliary excretion data). Whereas variations in uptake activity of
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transporters might have a profound influence on systemic concentrations, variations in
canalicular efflux might significantly affect liver concentrations without having an effect on
systemic exposure. (108) This is especially relevant for drugs for which the target sites for
effect or toxicity are within the hepatocyte. Therefore, quantitative estimations of liver
concentrations in vivo are necessary in order to investigate variations in efflux caused by
drug-drug interactions or transporter polymorphisms. Imaging approaches such as positron
emission tomography, magnetic-resonance imaging, and gamma scintigraphy have provided
important insights into the function of hepatic efflux proteins. (109, 110) Furthermore,
methods have been developed to quantify the biliary excretion of drugs in humans by
sampling duodenal fluid using, for example, nasobiliary or oroenteric tubes. (111, 112)
However, these sampling approaches are not used routinely because they are somewhat
invasive and require specialized, trained personnel and equipment.
Historically, single-pass in situ or isolated perfused liver studies have been carried out to
investigate the physiology and pathophysiology of the liver. In contrast to in vitro models
such as isolated hepatocytes and liver slices, the isolated perfused liver preserves hepatic
architecture, cell polarity, and bile flow. Furthermore, this model enables sampling of bile as
well as inflow and outflow perfusate simultaneously; also liver tissue is available at the end
of the study. This provides a rich data set amenable to pharmacokinetic modeling, making
the isolated perfused liver system extremely useful for mechanistic studies of hepatobiliary
transport. Unfortunately, this approach has limited applicability in humans. More recently,
hepatocytes cultured between two layers of gelled collagen (“sandwich-configuration”) have
been used to study hepatobiliary transport. Suspended hepatocytes, which are used primarily
for initial uptake studies, are not a suitable model for studying the role of hepatic efflux
proteins in drug/metabolite disposition because hepatocytes rapidly lose polarity after
enzymatic/mechanical disruption (113). By contrast, sandwich-cultured hepatocytes regain
mature hepatocyte morphology, reestablish cell polarity, form canalicular networks, and
maintain transporter and metabolic enzyme expression, and they are a suitable in vitro
model for studying hepatocyte efflux of drugs/metabolites. (114) Sandwich-cultured
hepatocytes from preclinical species and humans have been used to assess biliary clearance
as a measure to improve predictions of hepatic clearance. (114) However, species-related
differences in transport proteins may confound the translation of in vivo data generated in
preclinical species to humans.
Historically, vesicle transport assays using either canalicular or basolateral liver plasma
membranes isolated from hepatic tissue obtained from preclinical species or humans were
used to study carrier-mediated transport of endogenous compounds. This approach was used
to identify and characterize bile acid and bilirubin glucuronide transport across the
canalicular membrane, which led to the discovery of BSEP and MRP2. Naturally, these
membranes contain multiple transport proteins, and ATP-dependent basolateral efflux data
generated with basolateral liver plasma membranes may be confounded by uptake
transporters. Therefore, these systems are not useful for identifying specific substrates of
individual ATP-dependent binding cassette (ABC) efflux proteins. With the help of rapidly
evolving molecular biology techniques and identification of individual transport proteins,
this tissue-based vesicle assay system has been largely replaced by membrane vesicles
generated from vector-transfected or virus-infected bacterial, insect, and more recently
mammalian cells (e.g., HEK293, MDCKII, and LLC-PK1) expressing a single ABC-
transporter. Given their high-throughput capability, these membrane vesicles have now
become part of a standard approach to identify substrates and inhibitors of hepatic efflux
transport proteins. As our understanding of the roles of uptake and efflux transporters in
facilitating the vectorial transport of xenobiotics across the hepatocyte has evolved, the use
of polarized mammalian cells (e.g., MDCKII and LLC-PK1) has become more widely used
to identify substrates and inhibitors of hepatic transport proteins. The combined expression
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of uptake and efflux carriers enabled the analysis of vectorial transport, which is a key step
in hepatobiliary elimination. (115, 116) Double-transfected polarized cell lines were
developed in the early 2000s and are now valuable tools in studying transcellular transport.
Triple- and quadruple transfected cell lines OATP1B1/MRP2/MRP3 or MRP4, as well as
OATP1B1/OATP1B3/OATP2B1/MRP2 have been developed to predict hepatobiliary
processes more accurately. (117, 118) Recently, a triple-transfected cell line expressing
uptake and efflux transporters and a drug-metabolizing enzyme has been described to study
transporter-metabolism interplay. (119) To date, the level of recombinant expression cannot
be controlled, and this may limit the use of these cell systems to quantitatively predict
hepatobiliary transport. Furthermore, the expression of endogenous transporters in these
cells might mask the activity of the recombinant transporters and confound data
interpretation. (120) The ability of in vitro systems to accurately predict which transport
proteins are responsible for hepatic efflux in vivo depends not only on the substrate and its
relative affinity for individual transport proteins but also on the relative expression levels of
the proteins as compared with the in vivo situation. Quantitative absolute proteomics of drug
transport proteins will help to overcome this problem in the future and might enable the
establishment of scaling factors for in vitro-in vivo correlation. For OATP transporters,
Shitara et al. established a method to estimate the transporter contribution to overall
substrate uptake by comparing the ratio of uptake clearances of the test and the reference
compounds in overexpressing cell systems and in hepatocytes, and calculating a
proportionality (relative activity, R-) factor. (121) The results are based on the assumption
that the reference compound is specific for the respective transport protein; however, given
to the overlapping substrate spectrum of transport proteins, is hardly ever the case. (122)
Given the fact that uptake and metabolism are key steps in hepatobiliary elimination, it is
debatable whether a similar approach could be established for efflux transporters.
In addition to in vivo and in vitro systems, computational modeling and simulation has
become increasingly important in drug development. Quantitative Structure-Activity
Relationship (QSAR) studies have been used to identify substrate and inhibitor
characteristics for certain drug transporters. These studies can be used to screen compound
databases and predict whether new molecular entities are substrates or inhibitors of certain
transporters. In addition, physiologically-based pharmacokinetic modeling approaches
facilitate the translation of data generated from in vitro systems to the in vivo situation, and
enable predictions of the impact of altered clearance pathways on systemic drug disposition
and the pharmacokinetics of drugs/metabolites in the target tissue. (123)
5. Conclusions, Future Directions and Challenges
As highlighted in the previous sections, hepatic efflux transport proteins may markedly
affect the pharmacokinetics and/or pharmacodynamics of some drugs and hence their
therapeutic efficacy and/or toxicity. Our understanding of the role of hepatic efflux transport
proteins in human disease and pharmacotherapy has been evolving for more than half a
century. Numerous systems, including in vitro, in vivo, and in silico models, have been used
successfully to study the role of hepatic efflux transporters (Figure 6); the majority of the in
vitro systems were developed in the past decade. Each system has strengths and limitations;
however, to date, no single system can perfectly predict the contribution of hepatic efflux
transporters to overall drug disposition in humans in vivo. In the following section, some of
the current challenges and future directions in studying hepatobiliary efflux transport are
examined.
Cellular models
Currently, the availability of high quality human hepatocytes is a major limitation in
studying hepatic transport processes. Although techniques for cryopreservation have
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improved substantially over the past decade, there are considerable qualitative differences
between batches. Improved hepatocyte-derived cells might hold great promise for
overcoming these problems. For example, the human hepatoma HepaRG cell line closely
resembles human hepatocytes with respect to morphology as well as enzyme and transporter
expression. (124) If they are not terminally differentiated, HepaRG cells can be propagated
indefinitely, thereby providing a consistent supply of cells. Some challenges remain
regarding the use of HepaRG cells to evaluate the hepatic efflux of drugs and generated
metabolites because this model represents a mixed population (hepatocytes and biliary
epithelial cells). Inducible pluripotent stem cells (iPS) and human embryonic stem cells are
promising sources for large quantities of high quality, high purity hepatocytes. Current
strategies to differentiate iPS cells into hepatocytes using growth factors achieve
differentiation rates of up to 60–80%. (125) The use of stem cell-derived hepatocytes as a
substitute for primary human hepatocytes for studying and predicting hepatobiliary efflux of
drugs/metabolites will depend on their comparability to mature hepatocytes with respect to
morphology as well as transporter and enzyme expression. Further, improvements in
differentiation strategies are necessary to achieve 100% differentiation into hepatocytes and
to avoid costly isolation and purification processes.
Specific probes and inhibitors
Although in vitro models such as membrane vesicles and transfected cells facilitated the
identification of key transport proteins involved in hepatobiliary drug efflux, predicting the
contribution of any single efflux transporter to overall disposition remains a challenge.
Moreover, the broad substrate overlap between hepatic efflux transporters complicates
efforts to determine the role of any single transport protein. The search continues for specific
metabolically stable probes and/or inhibitors that do not affect metabolism; such compounds
would be useful tools, both in vivo and in vitro, to study the involvement of single proteins.
However, to date such probes have remained elusive.
In vitro – in vivo correlations
Despite the outstanding advances made in recent years in the field of drug transport and
disposition, there is a disproportionate amount of in vitro data relative to in vivo data, and
preclinical findings relative to clinical findings. Further research is needed to characterize,
validate, and refine existing model systems and techniques, and to develop new approaches
to assess hepatic efflux transport in humans. In order to accurately predict the
pharmacokinetics and pharmacodynamics of therapeutic agents in patients, a more holistic
understanding of the interplay among hepatic uptake, metabolism, intracellular disposition,
efflux, and the functional redundancy between transport proteins is needed. Also, further
information is required about the effects of disease states, genetic polymorphisms, and
environmental factors (e.g., alcohol consumption, diet, and smoking) on hepatic efflux
transport proteins. Modeling and simulation will be critical in obtaining improved in vitro-in
vivo correlations.
In vivo-imaging techniques
Noninvasive imaging techniques such as multiphoton microscopy and radionuclide/
fluorescent imaging may become powerful tools in elucidating drug disposition and
predicting drug-drug interactions in vivo. Positron emission tomography and magnetic-
resonance imaging (MRI) have been employed to determine drug disposition and transport
in vivo in animals as well as in humans. However, some limitations of these techniques exist
including low resolution and slow image acquisition (PET), the fact that there are only a
limited number of suitable contrast agents (MRI), and the need for specialized facilities/
equipment. At present, imaging agents must be metabolically stable because it is not
possible to differentiate between parent compound and generated metabolites. Recently,
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multiphoton imaging has enabled minimally invasive deep-tissue in vivo imaging. (126)
This technique has been used in mice to study the hepatic disposition of 6-
carboxyfluorescein diacetate using an intravital hepatic imaging chamber. (127) Given that
the tissue penetration depth is currently only about 500 μm, the applicability of intravital
imaging in humans is limited to specific tissues such as skin. The application of novel
technologies to quantify drugs and metabolites in vivo a non-invasive manner could lead to
major breakthroughs in our ability to investigate the role of efflux proteins in the
hepatobiliary disposition of drugs in patients.
Mass spectrometry imaging
Recently, mass spectrometry has emerged as a tool for the direct analysis of small molecule
pharmaceuticals and endogenous compounds in biological tissue. These techniques allow for
comprehensive assessment of the spatial distribution of parent drug and metabolite(s) in
tissues without the need to label compounds (autoradiography) or homogenize tissue, which
would result in a loss of information about distribution of the drug in tissue. A recent review
by Castellino et al. discusses these techniques in depth. (128)
Conclusion
Over the past decade, rapid technological advances have accelerated the rate of knowledge
acquisition about drug transport proteins. Discussions led by the International Transporter
Consortium have helped to focus research efforts on important questions in this field,
particularly those relating to drug development issues. (129) Currently, we have only a
limited ability to make accurate predictions of the influence of hepatic efflux transporters on
the pharmacokinetics/pharmacodynamics of drugs, and only a rudimentary knowledge
regarding the possible effects of changes in hepatic drug efflux (due to a disease or drug
interactions) on pharmacotherapy. However, great advances in this field are on the horizon,
as technical innovations in cell biology, engineering, chemistry, and mathematical modeling
provide more sophisticated and robust approaches addressing these important questions.
Such information is prerequisite to the ultimate goal of delivering personalized medicine.
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Figure 1. Localization of drug transport proteins in the liver
This figure was modified from Ho and Kim. (130)
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Figure 2. Schematic representation of progressive familial intrahepatic cholestasis (PFIC) type
2.<
br>Left panel: Under normal conditions BSEP transports bile acids into the bile. Right
panel: Mutation of the ABCB11/BSEP gene results in proteasomal degradation and/or
expression of a protein with low/no function, leading to reduced transport of bile acids into
bile and consequently accumulation of deleterious bile acids in the hepatocyte. The broken
lines represent minimal or no transport. ER, endoplasmatic reticulum.
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Figure 3. Schematic representation of Dubin-Johnson-Syndrome
Left panel: Under normal conditions, MRP2 excretes bilirubin-glucuronide into bile. Right
panel: Loss-of-function of MRP2 results in accumulation of bilirubin-glucuronide in the
hepatocyte. Increased MRP3 on the basolateral membrane of the hepatocytes transports
bilirubin-glucuronide into the sinusoidal blood, resulting in conjugated hyperbilirubinemia
in the systemic circulation. The broken lines represent minimal or no transport.
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Figure 4. Drug efflux transporters and toxicity in liver and intestine
Left panel liver and intestine: In the plasma or hepatocyte, the prodrug irinotecan
(CPT-11) is converted to SN-38 by carboxylesterases (CE). SN-38 is further glucuronidated
and excreted into bile. In the intestine, SN-38G is converted back to SN-38 by enteric
bacterial β-glucuronidases and is available for reabsorption. It has been hypothesized that
repeated exposure of enterocytes to SN-38 is hypothesized to be the cause of severe
diarrhea. Right panel (liver and intestine): Bile acids are taken up from the systemic
circulation by sodium-dependent taurocholate cotransporting peptide (NTCP) or OATPs, or
synthesized from cholesterol. The efflux of bile acids across the canalicular membrane into
bile is mediated primarily by the bile salt export pump BSEP (which transports
predominantly monovalent bile acids) and MRP2 (which transports sulfate and glucuronide
conjugates of bile acids). Under cholestatic conditions, MRP3, MRP4, and OSTα/β act to
efflux bile acids across the basolateral membrane into the blood. In the intestine, the apical
bile salt transporter ASBT and OATPs mediate the reuptake of bile acids. From the
enterocyte, bile acids are excreted by MRP3, MRP4, and OSTα/β into the mesenteric
circulation, and they ultimately flow into the portal vein. Inhibition of the major bile acid
transporter BSEP results in accumulation of cytotoxic bile acids, potentially causing liver
injury.
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Figure 5. Drug efflux transporters and efficacy
Top right panel: Statins are taken up into hepatocytes by OATP-mediated transport or
passive diffusion. They inhibit the main enzyme of cholesterol synthesis, HMG-CoA-
reductase. Excretion of statins into bile is mediated primarily by BCRP. Lower panel:
Effect of OATP and BCRP inhibition on the concentration-time profiles of statins in liver
and blood (modified from (108)). Top left panel: Morphine is metabolized to morphine-3-
and morphine-6-glucuronide followed by canalicular or basolateral efflux. In the systemic
circulation, morphine-6-glucuronide contributes to the antinociceptive effect of morphine;
morphine-glucuronides (morphine-G) are excreted primarily via the kidney.
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Timeline of important discoveries and model systems in the field of drug efflux transport
proteins.
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